Abbott Laboratories (ABT)

43.60
NYSE : Health Care
Prev Close 43.60
Day Low/High 0.00 / 0.00
52 Wk Low/High 36.00 / 51.24
Avg Volume 10.86M
Exchange NYSE
Shares Outstanding 1.47B
Market Cap 63.78B
EPS 2.90
P/E Ratio 33.39
Div & Yield 1.04 (2.40%)

Latest News

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Abbott Labs (ABT) Stock Price Target Raised at Barclays

Abbott Labs (ABT) Stock Price Target Raised at Barclays

Abbott’s (ABT) stock price target was increased to $50 from $48 at Barclays following the company’s 2016 second quarter results.

Abbott's Alere Deal Continues To Face Uncertainty

Abbott's Alere Deal Continues To Face Uncertainty

The medical device company has two pending acquisitions worth just under $40 billion combined.

St. Jude Medical Up Slightly as It Meets Estimates

St. Jude Medical Up Slightly as It Meets Estimates

The company reported flat but in line earnings of $1.06 per share.

Abbott Labs (ABT) Stock Rising on Q2 Earnings Beat

Abbott Labs (ABT) Stock Rising on Q2 Earnings Beat

Abbott Labs (ABT) 2016 second quarter results surpassed analysts’ expectations.

Trade-Ideas: Abbott Laboratories (ABT) Is Today's Post-Market Leader Stock

Trade-Ideas: Abbott Laboratories (ABT) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Abbott Laboratories (ABT) as a post-market leader candidate

Abbott Labs (ABT) Stock Falling Ahead of Q2 Earnings Report

Abbott Labs (ABT) Stock Falling Ahead of Q2 Earnings Report

Abbott Labs (ABT) will report 2016 second quarter earnings on Wednesday, July 20 before the market opens.

How to Profit From Abbott Labs

How to Profit From Abbott Labs

Abbott Labs -- with its 2.5% dividend yield and market underperformance -- will look safer when the market begins to rotate out of hotter stocks.

5 Big Medtech Stocks Investors Love Right Now -- but Should You Buy Them?

5 Big Medtech Stocks Investors Love Right Now -- but Should You Buy Them?

Can medical technology stocks continue their momentum higher in the second half of the year? Investors say yes, but technical analysis says not necessarily.

What to Look for When Abbott Labs (ABT) Reports Q2 Earnings

What to Look for When Abbott Labs (ABT) Reports Q2 Earnings

Abbott Labs (ABT) is scheduled to report 2016 second-quarter financial results before the market open on Wednesday.

Jim Cramer's 'Mad Money' Recap: Watch for Earnings, Opportunities Next Week

Jim Cramer's 'Mad Money' Recap: Watch for Earnings, Opportunities Next Week

Jim Cramer will be watching a host of earnings next week. In addition, he offers his playbook for financial literacy.

Analyst Sees No Major Concerns on Regulatory Front for Abbott-St. Jude Medical Deal

Analyst Sees No Major Concerns on Regulatory Front for Abbott-St. Jude Medical Deal

Wedbush analyst Tao Levy also does not expect to see rival offers to emerge for St. Jude Medical.

FDA Approves The Tecnis Symfony® Intraocular Lenses, The First And Only Extended Depth Of Focus Lenses For People With Cataracts

FDA Approves The Tecnis Symfony® Intraocular Lenses, The First And Only Extended Depth Of Focus Lenses For People With Cataracts

- Approval includes Toric version of Symfony IOL for people with astigmatism

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the health services industry lower today.

Abbott Labs (ABT) Stock Gaining on Absorbable Stent Effectiveness

Abbott Labs (ABT) Stock Gaining on Absorbable Stent Effectiveness

Abbott Labs (ABT) absorbable stent, which was approved by the FDA last week, has gone into its first patients.

Trending Tickers: SWN, ABT, AAL, UAL, EW

Oil began to rebound Wednesday from steep declines earlier this week.

Abbott Laboratories (ABT) Stock Slumps Despite FDA Approval

Abbott Laboratories (ABT) Stock Slumps Despite FDA Approval

Abbott Laboratories (ABT) won approval for an absorbable stent this morning, but the stock is falling.

FDA Approves Abbott's Absorb™ Bioresorbable Stent, The Only Fully Dissolving Heart Stent

FDA Approves Abbott's Absorb™ Bioresorbable Stent, The Only Fully Dissolving Heart Stent

- Revolutionary device made of naturally dissolving material

12 High-Yield Stocks From Deutsche Bank's Best Long Ideas

12 High-Yield Stocks From Deutsche Bank's Best Long Ideas

Following Brexit volatility, Deutsche Bank offered investors 42 best long ideas; here's the 12 stocks from the list with the highest dividend yields.

Traders, Here's Your 'Short' Notice

They should wait until the rally appears to be running out of steam in order to go in on the short side.

NYSE's New Highs Caught My Eye

Let's not overthink it; this is a good thing.

Medtronic Acquires HeartWare With Some Activist Inspiration

Medtronic Acquires HeartWare With Some Activist Inspiration

Engaged Capital agitated against the cardiac medical device maker's buy of an Israeli company and pushed for a new board member that once led the acquirer's M&A efforts.

'Mad Money' Lightning Round: Intel Is Just Treading Water

'Mad Money' Lightning Round: Intel Is Just Treading Water

Cramer likes Abbott Labs and United Technology but is no fan of Nevsun Resources.

Jim Cramer's 'Mad Money' Recap: We Need More Mergers Right Now

Jim Cramer's 'Mad Money' Recap: We Need More Mergers Right Now

There are way too many companies but the U.S. government has thrown a chill into M&A, Cramer says.

Abbott Laboratories (ABT) Marked As A Barbarian At The Gate

Abbott Laboratories (ABT) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Abbott Laboratories (ABT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Abbott Laboratories (ABT) Stock Down, Jefferies Raises Price Target

Abbott Laboratories (ABT) Stock Down, Jefferies Raises Price Target

Shares of Abbott Laboratories (ABT) are lower on Tuesday but Jefferies increased its price target on the stock, advising investors to 'be patient.'

Abbott Announces Positive Results From Groundbreaking Study Of FreeStyle® Libre System For People With Type 1 Diabetes

Abbott Announces Positive Results From Groundbreaking Study Of FreeStyle® Libre System For People With Type 1 Diabetes

- STUDY SHOWS THAT FREESTYLE® LIBRE SYSTEM SIGNIFICANTLY REDUCES HYPOGLYCEMIA IN PEOPLE WITH TYPE 1 DIABETES WITHOUT INCREASING HBA1C, COMPARED TO ROUTINE SELF-MONITORING OF BLOOD GLUCOSE (TRADITIONAL FINGER STICKING)